THERAFLU COLD & COUGH HOT LIQUID OTC
Generic Name and Formulations:
Dextromethorphan HBr 20mg, pheniramine maleate 20mg, phenylephrine HCl 10mg; pwd packet; natural lemon flavor; contains sodium 46mg per packet.
Novartis Consumer Health
Indications for THERAFLU COLD & COUGH HOT LIQUID:
Nasal and sinus congestion, cough, rhinorrhea.
Dissolve contents of 1 packet into 8oz hot water; sip while hot. Consume entire drink within 10–15mins. Take every 4 hours; max 6 packets/24hrs.
During or within 14 days of MAOIs.
Cardiovascular disease. Hypertension. Thyroid disease. Diabetes. GI or GU obstruction. Glaucoma. Asthma. Lower respiratory disorders. Sodium-restricted diet. Discontinue if symptoms worsen or persist for ≥7days. Pregnancy. Nursing mothers.
Antitussive + antihistamine + sympathomimetic.
See Contraindications. Avoid alcohol. Hypertensive crisis with MAOIs. β-blockers may increase the pressor effects of sympathomimetics. Antihypertensives antagonized. Increased CNS effects with other CNS depressants.
Drowsiness, anticholinergic effects, nervousness, dizziness, insomnia, excitability in children.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC